RxDoctor Payments Data

Sonia Shah-Pandya, MD

Internal Medicine · Midlothian, VANPI 1225053697

Payments from drug & device makers

$7,443in general payments, 2019–2025

Across 455 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$741
  • Amgen$532
  • AstraZeneca$479
  • Lilly USA, LLC$411
  • Boehringer Ingelheim$311
  • plus $4K from 51 others

What the payments were for

  • Food & beverage$7,30998%
  • Education$1342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)77$1,057
Novo Nordisk52$741
Amgen(2 entities)35$532
AstraZeneca26$479
Lilly USA, LLC27$411
Boehringer Ingelheim19$311
Pfizer19$279
Abbott11$250
GSK16$226
Merck14$213
Astellas Pharma US Inc8$195
Exact Sciences9$169
Takeda Pharmaceuticals U.S.A., Inc.10$166
Dexcom, Inc.8$153
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$138
Otsuka America Pharmaceutical, Inc.5$132
Teva Pharmaceuticals USA, Inc.8$129
Sanofi-aventis U.S. LLC9$126
Inspire Medical Systems, Inc.4$109
Bayer8$104
Corium, LLC6$98
Insightec,inc2$92
Biohaven Pharmaceutical Holding Company Ltd.4$90
Biogen5$85
Amarin Pharma, Inc.4$84
Novartis5$83
Actelion Pharmaceuticals US, Inc.4$82
Dynavax Technologies Corporation5$77
Sumitomo Pharma America, Inc.4$77
Esperion Therapeutics, Inc.4$76
Integra Lifesciences Corporation1$76
Genentech USA, Inc.5$64
Eisai Inc.3$54
Biohaven Pharmaceuticals, Inc.2$44
Kowa Pharmaceuticals America, Inc.3$42
Edwards Lifesciences2$36
Cequr Corporation1$32
Shire North American Group Inc2$25
E.r. Squibb & Sons, L.L.C.2$25
Daiichi Sankyo Inc.1$23
Medtronic1$18
Bausch Health US, LLC1$18
Xeris Pharmaceuticals, Inc.1$18
Philips North America LLC1$18
Jazz Pharmaceuticals Inc.1$18
Scpharmaceuticals Inc.1$17
Nestle Healthcare Nutrition Inc.1$16
Antares Pharma, Inc.1$16
Tactile Systems Technology Inc1$15
Currax Pharmaceuticals LLC1$15
Ultragenyx Pharmaceutical Inc.1$15
Watermark Medical, Inc.1$14
Johnson & Johnson1$13
Circassia Inc.1$13
Arbor Pharmaceuticals, Inc.1$12
Amneal Pharmaceuticals LLC1$12
Clarus Therapeutics Inc.1$10

How this compares

$7,443 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$186,439
Medicare patients
574
Services billed
1,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide132$150,931
EliquisApixaban95$107,128
Wellbutrin XlBupropion Hcl12$69,894
TrulicityDulaglutide29$57,646
JardianceEmpagliflozin39$55,336
MyrbetriqMirabegron52$33,024
FarxigaDapagliflozin Propanediol34$30,958
XareltoRivaroxaban16$26,442
LinzessLinaclotide22$16,142
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$15,930
MounjaroTirzepatide12$14,755
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$11,339
Mirabegron ErMirabegron15$10,635
BelsomraSuvorexant14$9,453
SymbicortBudesonide/Formoterol Fumarate16$6,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$741$150,931132 claims
PfizerEliquis$279$107,12895 claims
Lilly USA, LLCTrulicity, Mounjaro$411$72,40241 claims
Boehringer IngelheimJardiance$311$55,33639 claims
AstraZenecaFarxiga, Symbicort, Brilinta$479$42,87462 claims
Astellas Pharma US IncMyrbetriq$195$33,02452 claims
Johnson & JohnsonXarelto$13$26,44216 claims
AbbVieLinzess, Synthroid$1,057$22,627135 claims
GSKTrelegy Ellipta$226$15,93026 claims
MerckBelsomra$213$9,45314 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$4,344488 claims
Kowa Pharmaceuticals America, Inc.Bystolic$42$3,59414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →